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[~  Paediatric Cystic Fibrosis care - at a District General Hospital 
S. Nagvekar 1 , A. Ahuja 1 , A. Hannam 2, L. Alker 2. 1Department of Paediatrics, 
Royal Albert Edward Infirmary, 2paediatric Respiratory Team, Ashton, Wigan and 
Leigh Primary Care Trust, Wigan UK 
Aims: To demonstrate he effectiveness of the care given by a District General 
Hospital CF team within a regional shared care system. 
Methods: As a part of annual CF audit, case notes of 23 CF patients under the care 
of Royal Albert Edward Infirmary, Wigan, sharing care with Alder Hey Children's 
hospital, Liverpool were analysed for various parameters including rowth, chronic 
infection rates, lung functions (FEV1), Schwachman annual scores and Northern 
X-ray scores. The cumulative data over the period of 10 years 1995 2004 were 
obtained. These were compared with available national and international data. 
Results: Our results identified that the children's growth is near normal. The average 
lung function has improved steadily over the last 10 years mean FEV1 being 98% at 
16 years of age. Although our rate of infection acquisition is the same, our chronic 
infection rate is currently lower than available figures. Average Schwachman a nual 
scores were in the range 86 100 in 87% of the patients. Consistent improvement 
trend was noticed over last 10 years average score being 74% in 1995, 84% in 
2000 and 89% in 2004. Northern X-ray scores were in the range 0 4 in 86% of 
the patients and were in the range 5 9 in 14% of the patients. 
Conclusions: It is widely accepted that high standards of care can go a long way to 
improve prognosis in Cystic Fibrosis. It is evident that the care given by a local team 
within a District General Hospital on shared care basis appears to be as effective 
as care given solely by a specialist centre. 
11. Epidemiology 
l~  Cystic Fibrosis in Iceland 1955-2005; incidence, survival and 
CFTR mutations in the Icelandic population 
H. Bergsteinsson 1 , O. Baldursson 2, M. Clausen 1, E. Cook 3, I. Olafsson 3. 
1 Childrens Hospital Iceland, 2Division of Pulmonary Medicine, 3Department of 
Clinical Biochemistry, Landspitali University Hospital Iceland 
During the past 50 years, 27 patients have been diagnosed with cystic fibrosis (CF) 
in the Icelandic population of approximately 300.000. The calculated incidence is 
1/8344 live births. Of the 16 females and 11 males diagnosed, six females and six 
males are presently alive. Twelve patients died at age ten or younger. The 16 CF 
patients born before 1973 are all deceased except wo; one had a successful lung 
transplantation two years ago, the other has deteriorating lung function. Of the 8 
patients born in Iceland after 1980 only one has chronic Pseudomonas eruginosa 
airway infection. 
The causative mutations in the CFTR gene have been detected in 21 of the 27 
CF patients. The remaining six patients died before 1970. Three different mutations 
were found: AF508; 24 alleles (57%), N1303K; 16 alleles (38%), 1078dT; 2 alleles 
(5%). Using PCR and PFLPs we screened for the presence of these mutated alleles 
in a control population (n 322). The allele frequency was 0.9%, 0.5% and 0.0% 
for AF508, N1303K and 1078dT, respectively. 
Conclusions: The incidence of CF is low in Iceland compared to the other nordic 
countries. Potential explanations include underdiagnosis, which is unlikely given 
the access to specialized medical care in Iceland, limited gene pool of the original 
settlers of Iceland or an effect from severe "population bottle necks" during 
the middle ages. Consistent with data from other countries, life expectancy of 
CF patients has improved uring the last 25 years. Unlike other studies, ours only 
found three types of CF mutations. Finally, airway colonization with Pseudomonas 
aeruginosa may be less common among our patients than in other countries. 
I• Effects of socioeconomic status, race and ethnicity on quality of 
life in a national database 
A. Quittner 1, M. Schechter 2, L. Rasouliyan 3, D. Pasta 3, J. V~agener 4. For the 
Investigators arid Coordinators of the Epidemiologic Study of Cystic Fibrosis 
(ESCFII). 1 Univ. of Miami, FL; 2Brown Univ., RL' 3 Ovation Research Group, CA; 
4 Genentech, Inc., CA, USA 
Objectives: There is little data on how demographic characteristics affect quality of 
life (QOL) for patients with CE We hypothesized that lower SES and membership n a 
racial or ethnic minority would be associated with worse QOL, controlling for disease 
variables. 
Methods: The CF Questionnaire-Revised (CFQ-R [1]) was completed uring stable 
visits by patients and parents in ESCFII. SES was indicated by State Insurance coverage 
and patients were categorized as Hispanic (H), African-American (AA), or Caucasian 
by self-identification. Multivariate models tested the independent contributions of SES 
and race/ethnicity after controlling for medical characteristics (FEV1, gender, weight 
and height Z-scores, pseudomonas, pancreatic enzymes). 
Results: The CFQ-R was administered to 2115 adults (56 H, 52 AA), 944 adoles- 
cents (39 H, 29 AA), 1750 children (110 H, 56 AA), and 1646 parents (115 H, 
65 AA). Effects of SES (controlling for race/ethnicity and medical characteristics) 
and race/ethnicity (with controls for SES and medical characteristics) are as follows. 
Low SES adults had worse scores on all CFQ-R scales except Weight. H adults had 
worse scores on the Emotional scale; AA adults had worse scores on the Weight scale. 
Low SES adolescents had worse Physical and Role Functioning. H adolescents had 
lower Role and Social Functioning and worse Vitality than AA teens; AA teens reported 
worse Social Functioning. Low SES parents had worse scores on: Physical, Vitality, 
Emotional, Treatment Burden, Health Perceptions, Respiratory, Digestion, and School; 
H parents had lower scores on Physical and higher scores on Digestion. Low SES chil- 
dren had worse Physical, Emotional, Social, Body Image, Treatment Burden and Res- 
piratory scores. Both Hand AA children reported lower scores on Social Functioning. 
Conclusions: After accounting for medical variables, poverty was associated with 
pervasive negative ffects on QOL across the lifespan. Race/ethnicity had effects on 
QOL independent of SES, particularly social and role functioning. 
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I • C F  National registry in Slovakia 
H. Kayserova 1 , D. Zlochova 1 , B. Remig 1, J. Orosova 1 , A. Feketeova 2, B. Takac 3, 
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Aims: From 1995, when 135 CF pts. were on Slovak CF Registry raised the number 
to 447 in 2005 with 447 surviving (225M, 222F, mean age 16.1yrs). 164 pts. 
(46.9%) are adult. All CF patients are genetically evaluated, but in 155 (44.3%) is 
the CFTR mutations till unknown. The mean age of death was 6.7yrs, but in 10 
pts dying in last 6 years it was 17.7yrs. 
Methods: Using CF database prevalence of CF typical clinical symptoms is 
described. 
Results: Prevalence of delF508 is only 36.9%, 69 pts (19.7%) are homozygous, 
104 (30.5%) compound heterozygous for delF508. Meconium ileus: 20 pts. (5.7%), 
DIOS: 28 pts. (8%), CFRDM: 20 pts. (5.7%), liver disease: 170 pts.(48.6%) 
cirrhosis: 22 pts. (6.3%), rec. pancreatitis: 40 pts. (11.4%), rectal prolaps: 25 pts. 
(7.1%), nasal polyps: 75 pts. (21.4%), chronic Pseudomonas sp. colonization: 150 
pts. (42.9%) from the age of 9.3yrs; Burkholderia sp.: 51 pts. (14.6%) from the 
age of 15.2yrs. Mean lung function: FEVI: 85.0%, FVC: 85.3%, HRCT score 
acc. Bhalla: right: 6.2, left: 5.0. Mean BMI: 18.5, height z-score: -0.47. Treatment: 
Pulmozyme: 135 pts. (38.6%), inhaled antibiotics: 128 pts. (36.6%), UDCA: 146 
pts.(41.7%), enteral supplements: 146 pts. (41.7%), corticosteroids: 53 pts. (15.1%), 
macrolides: 94 pts. (26.9%), pancreatic enzymes: 253 pts. (72.3%) 
Conclusion: Data allow quickly analysis of clinical features, correlation with CFTR 
genotype, important factors of surviving, type and efficacy of treatment. There is 
need of evaluating of more than 30 CFTR mutations in CF gene in Slovakia 
